Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 2
Submit an article Journal homepage
4,132
Views
15
CrossRef citations to date
0
Altmetric
Special report

Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors

Manuel Carcaoa Division of Haematology/Oncology and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, CanadaCorrespondence[email protected]
View further author information
,
Maria Elisa Mancusob Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-7113-4028View further author information
ORCID Icon,
Guy Youngc Children’s Hospital Los Angeles, Los Angeles, University of Southern California Keck School of Medicine, CA, USAORCID Iconhttps://orcid.org/0000-0001-6013-1254View further author information
ORCID Icon &
Víctor Jiménez-Yusted Haematology Department, Hospital Universitario La Paz, Autónoma University, Madrid, SpainORCID Iconhttps://orcid.org/0000-0003-3937-3499View further author information
ORCID Icon
Pages 143-148 | Received 18 Nov 2020, Accepted 11 Jan 2021, Published online: 27 Jan 2021

References

  • Hay CR, Palmer B, Chalmers E, et al. United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117:6367–6370.
  • Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–4055.
  • Fischer K, Lassila R, Peyvandi F, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015;113:968–975.
  • Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
  • van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134:317–320.
  • Hay CRM, DiMichele DM. International immune tolerance study collaborators. The principal results of the international immune tolerance study: a randomized dose comparison. Blood. 2012;119:1335–1344.
  • Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–2053.
  • Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818.
  • Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127–2138.
  • Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–822.
  • Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295–e305.
  • Bravo MI, Raventós A, Pérez A, et al. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro. J Thromb Haemost. 2020;18:1934–1939.
  • Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891–1899.
  • Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132:633.
  • Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25:676–684.
  • Brackmann HH, White GC 2nd, Berntorp E, et al. Immune tolerance induction: what have we learned over time? Haemophilia. 2018;24(Suppl 3):3–14.
  • Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25:789–796.
  • U.S. National Library of Medicine. ClinicalTrials.gov. emicizumab PUPs and Nuwiq ITI study. [cited 2020 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04030052
  • Bertolet M, Brooks MM, Ragni MV. The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia. Blood Adv. 2020;4:5433–5441.
  • U.S. National Library of Medicine. ClinicalTrials.gov. Phase III multi-center, randomized, controlled inhibitor eradication trial, comparing Eloctate immune tolerance induction (ITI) plus emicizumab vs. Eloctate ITI alone to eradicate inhibitor formation in severe hemophilia A. [cited 2020 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04303572
  • U.S. National Library of Medicine. ClinicalTrials.gov. Multicenter, randomized phase III inhibitor prevention trial, comparing Eloctate vs. emicizumab to prevent inhibitor formation in severe hemophilia A. [cited 2020 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04303559
  • U.S. National Library of Medicine. ClinicalTrials.gov. MOdern Treatment of Inhibitor-PositiVe PATiEnts with haemophilia A - An international observational study. Treatment of hemophilia A patients with FVIII inhibitors (MOTIVATE). [cited 2020 Dec 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04023019
  • Young G. How I treat children with haemophilia and inhibitors. Br J Haematol. 2019;186:400–408.
  • Antun A, Monahan PE, Manco-Johnson MJ, et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost. 2015;13:1980–1988.
  • Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–1939.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.